JAPhA Practice Innovations最新文献

{"title":"Deprescribing sulfonylureas in patients over the age of 65 within the Boise VA Medical Center","authors":"Natalie Everett,&nbsp;Robyn Cruz,&nbsp;Leanne Ertle,&nbsp;Elaine Nguyen","doi":"10.1016/j.japhpi.2025.100051","DOIUrl":"10.1016/j.japhpi.2025.100051","url":null,"abstract":"<div><h3>Background</h3><div>There are hypoglycemia-related safety concerns with sulfonylureas, especially in older adults with type 2 diabetes mellitus (T2DM). Clinical pharmacist practitioners working in primary care clinics have the opportunity to address these concerns and potentially optimize patients’ diabetes medication regimens through deprescribing of potentially unsafe sulfonylureas.</div></div><div><h3>Objective</h3><div>This study aimed to assess the impact of a pharmacist-led sulfonylurea deprescribing campaign in older adults with T2DM in the primary care setting of a Veterans Affairs medical center.</div></div><div><h3>Methods</h3><div>This was a prospective sulfonylurea deprescribing campaign conducted over a period of approximately 5 months at a single institution. Patients were enrolled if they were older than 65 years with an active sulfonylurea prescription, had an A1c of less than 8%, and were on select primary care teams. The primary project evaluator telephoned eligible patients to invite them to participate in a sulfonylurea deprescribing initiative, with those accepting then receiving a scheduled call to deprescribe their therapy and at least 1 subsequent follow-up call to assess changes in blood glucose. The primary end point was the percentage of patients successfully deprescribed from sulfonylurea therapy. Secondary end points were the number of patients requiring diabetes therapy adjustment and the number of follow-up visits required to optimize antidiabetic medications after sulfonylurea discontinuation.</div></div><div><h3>Results</h3><div>Nineteen patients received the sulfonylurea deprescribing intervention. Of these patients, 11 were able to successfully discontinue therapy with 3 of these patients requiring additional antidiabetic medication adjustments. Nine patients who received the intervention needed only 1 follow-up visit. At the time of data collection, 4 patients were still undergoing therapy adjustments after their initial sulfonylurea discontinuation.</div></div><div><h3>Conclusion</h3><div>This pharmacist-led sulfonylurea deprescribing campaign was successful. However, it did require substantial pharmacist involvement with some patients needing extended follow-up.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100051"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding horizons: Resident research makes its debut in JAPhA Practice Innovations","authors":"Darin C. Ramsey PharmD, BCPS, BCACP","doi":"10.1016/j.japhpi.2025.100054","DOIUrl":"10.1016/j.japhpi.2025.100054","url":null,"abstract":"","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining patient motivators to receiving the respiratory syncytial virus vaccine in the community pharmacy setting","authors":"Sarah Stetzer,&nbsp;Cherokee Layson-Wolf,&nbsp;Hyunuk Seung,&nbsp;Eric Kim,&nbsp;Vicki Bulkin,&nbsp;Deanna Tran","doi":"10.1016/j.japhpi.2025.100036","DOIUrl":"10.1016/j.japhpi.2025.100036","url":null,"abstract":"<div><h3>Background</h3><div>A single respiratory syncytial virus (RSV) vaccine dose is indicated for all adults 75 years of age and older and adults 60 to 74 years of age if they are at an increased risk of severe RSV disease. It is important for community pharmacists to understand which marketing methods are the key motivators for patients to receive the RSV vaccine given that they are among the most accessible health care professionals.</div></div><div><h3>Objectives</h3><div>The primary objective is to determine which marketing methods are the main factors that affect patients’ decisions to receive the RSV vaccine. The secondary objective is to determine which marketing methods influence certain demographics of patients.</div></div><div><h3>Methods</h3><div>An anonymous, 8-item survey was administered to individuals and data collection occurred from December 2023 to March 2024. The survey collected information about participants’ comorbidities, how participants heard about the RSV vaccine, what marketing tactics were most influential in their decision to receive the RSV vaccine, and other nonmarketing factors that may have motivated participants.</div></div><div><h3>Results</h3><div>Forty-eight surveys were collected and analyzed. More than half of the participants did not report any comorbid conditions (52.1%). The most frequently reported comorbid conditions were diabetes (25%) and chronic lung disease (18.8%). Television, commercials or news (62.5%), and primary care providers (54.2%) were selected as the 2 most frequently reported ways participants had heard about the RSV vaccine. Of all the available marketing methods provided, participants chose primary care providers (41.7%) as having the most influence on their decision to get the RSV vaccine.</div></div><div><h3>Conclusion</h3><div>These findings give insight into which marketing methods are more likely to influence patients to receive the RSV vaccine. Primary care providers were found to be the primary motivators for participants to receive the RSV vaccine. This study reinforces the importance of community pharmacists’ partnerships with providers to help increase access to information and receipt of RSV vaccination.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying barriers and facilitators to pharmacist-dietitian collaboration to optimize patient health: A focus group study","authors":"Daniel Hough,&nbsp;James Knight,&nbsp;Kimberlee Kilgore Meade,&nbsp;Christopher Pegg,&nbsp;Andrew Beard,&nbsp;Leanne J. Rein,&nbsp;Kenneth C. Hohmeier","doi":"10.1016/j.japhpi.2025.100052","DOIUrl":"10.1016/j.japhpi.2025.100052","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to identify barriers and facilitators to pharmacist-dietitian collaboration by identifying behavioral themes using the COM-B model.</div></div><div><h3>Design</h3><div>This was a qualitative research study using focus groups.</div></div><div><h3>Setting and participants</h3><div>The study was conducted at a single region of a nationwide supermarket pharmacy chain. Focus group participants were pharmacists employed by the pharmacy.</div></div><div><h3>Outcome measures</h3><div>The COM-B model was used to develop questions for the focus group guide. The focus group covered topics such as pharmacists’ knowledge of dietitian services, patient identification and referral processes, medical conditions, workflow integration, time and impact on workflow, pharmacists’ perceived patient reactions, service costs, incentives, general thoughts on referrals, potential benefits and concerns, and demographic information focus group sessions were recorded, transcribed, and analyzed using a rapid analysis technique to categorize text segments using COM-B model domains.</div></div><div><h3>Results</h3><div>A total of 3 focus groups containing 4-5 pharmacists each were completed. Three themes were identified from the rapid analysis: theme 1, knowledgeability of dietary program and motivation to refer; theme 2, barriers and perceptions by pharmacists related to the dietary service; and theme 3, gaps in communication and collaboration.</div></div><div><h3>Conclusion</h3><div>There were several identified barriers and facilitators to improving pharmacist-dietitian collaboration. Future research is needed to explore how best to address these barriers and facilitators to scale collaboration.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the impact of pharmacist-delivered educational intervention on the willingness to receive HPV vaccine in a dental clinic in New York","authors":"Julian Azzouzi ,&nbsp;Joanne Son ,&nbsp;Katrin Tamari ,&nbsp;Eric Wachs ,&nbsp;Elizabeth J. Unni","doi":"10.1016/j.japhpi.2025.100053","DOIUrl":"10.1016/j.japhpi.2025.100053","url":null,"abstract":"<div><h3>Background</h3><div>Human papillomavirus (HPV) infections are the leading cause of oral and oropharyngeal cancers in the United States, accounting for 70% of new diagnoses. An estimated 90% of newly diagnosed HPV-attributed cancer cases could be preventable with HPV vaccination before exposure, given that the vaccine is 100% effective for at least 12 years. Collaboration between dentists and pharmacists to enhance patient-centered care and vaccine education holds considerable potential to increase HPV vaccine rates among persons aged 9-26 years. Current literature exploring interprofessional collaboration between dentists and pharmacists suggests this partnership may address gaps in patient care, although examples of HPV vaccine initiatives are limited.</div></div><div><h3>Objective</h3><div>This study aimed to assess the impact of screening dental patients’ HPV vaccine status and providing pharmacist-led education and counseling on the intent of patients or guardians to receive the HPV vaccine.</div></div><div><h3>Methods</h3><div>Approved by the institutional review board, a cross-sectional prospective review of patients was conducted at a dental clinic. Patients aged 18-26 years and those aged 9-17 with consenting guardians who had not received the HPV vaccine, verified via the New York State Immunization Information System, were included. Enrolled participants received pharmacist-led education and counseling on HPV and the vaccine, including an educational handout. After the intervention, participants were surveyed to assess their interest in receiving the HPV vaccine. Statistical analysis used a 1-sample proportion test.</div></div><div><h3>Results</h3><div>A total of 67 patients and guardians were approached after prospective review, 32 agreed to participate, 13 were excluded, and a total of 19 were enrolled in the study. After pharmacist intervention, the proportion of participants’ intent to receive the HPV vaccine was 0.895 (<em>P</em> &lt; .001; 95% CI, 0.76–1.00).</div></div><div><h3>Conclusion</h3><div>Screening dental patients’ HPV vaccine status, paired with pharmacist-delivered HPV education and HPV vaccine counseling, may positively affect unvaccinated patients’ or guardians’ intent to receive the HPV vaccine.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a Drug Take Back Day event at a large chain community pharmacy","authors":"Kayla Pangilinan,&nbsp;Jessica McDaniel,&nbsp;Pramit Nadpara,&nbsp;Jean-Venable R. Goode","doi":"10.1016/j.japhpi.2025.100042","DOIUrl":"10.1016/j.japhpi.2025.100042","url":null,"abstract":"<div><h3>Background</h3><div>Medication accumulation is a growing public health concern associated with misuse, overdose, pollution, and wasted health care expenditures. Mitigation strategies such as Drug Take Back Day remain underutilized owing to a lack of awareness and access.</div></div><div><h3>Objectives</h3><div>This study aimed to analyze the quantity and characteristics of medications collected, assess donor knowledge and attitudes on safe medication disposal and reasons for medication accumulation, identify patient education opportunities, and compare data collected at 2 drug take back site locations.</div></div><div><h3>Methods</h3><div>Descriptive cross-sectional study conducted at 2 Drug Take Back Day events hosted by a large chain community pharmacy, 1 urban and 1 suburban. Disposed medication characteristics were recorded for the urban site only owing to restrictions from law enforcement, including product name, strength, dosage form, route of administration, category, drug class, length of treatment, condition, and controlled substance schedule. The number of donors and education brochures distributed was tracked, and medications were weighed at conclusion. A 17-question survey was offered to donors 18 years or older to assess demographics, characteristics of disposed medications, and knowledge and attitudes on safe medication disposal. Descriptive statistics were used to analyze results.</div></div><div><h3>Results</h3><div>A total of 311 medications were collected at the urban site. Most were expired noncontrolled prescriptions including supplements and vitamins, analgesics, and cardiovascular drugs. Forty of 246 donors completed the survey. The most identified reasons for excess medication were patient’s death, “excessive quantity,” and medication discontinuation. Eighty percent considered environmental concerns, 48% diversion prevention, and 30% fear of addiction or dependence reasons for participation. Twenty-one donors disposed of 67.8 pounds and 225 donors disposed of 600.9 pounds of medications, with 108 and 250 educational brochures distributed at urban and suburban sites, respectively.</div></div><div><h3>Conclusion</h3><div>Medications collected at Drug Take Back Day were expired noncontrolled prescriptions. Donors valued the environment and poison prevention over diversion and addiction concerns.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100042"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of GLP-1 agonists vs. other weight management medications in obese and overweight patients","authors":"Arielle Davidson,&nbsp;Christina Inteso,&nbsp;Nolan Rossman,&nbsp;Toni Larson,&nbsp;Kathryn Dudzinski","doi":"10.1016/j.japhpi.2025.100046","DOIUrl":"10.1016/j.japhpi.2025.100046","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 (GLP-1) agonists are efficacious for weight management; however, there are barriers that prevent access. Although studies have shown the efficacy of individual treatments, there is a lack of evidence that compares different classes of weight management medications with each other.</div></div><div><h3>Objective</h3><div>This study aimed to compare the efficacy of GLP-1 agonists with other classes of weight management medications.</div></div><div><h3>Methods</h3><div>This retrospective chart review included patients prescribed a weight management medication by a primary care pharmacist at Corewell Health between June 1, 2022, and June 1, 2023. Patients were assigned to (1) the GLP-1 agonist group or (2) the non-GLP-1 agonist group. The primary outcome was the percentage of patients who reached ≥ 5% weight loss at the end of the treatment course. The secondary outcomes include the percentage of patients who reached ≥ 10% weight loss and ≥ 15% weight loss at the end of the treatment course and average change in body mass index (BMI) at the end of the treatment course.</div></div><div><h3>Results</h3><div>A higher number of patients in the GLP-1 agonist group achieved the primary end point of ≥ 5% weight loss compared with the non-GLP-1 agonist group (29 patients [50.9%] vs. 17 patients [30.9%], <em>P</em> = 0.0318). A logistic model was done, which showed that, when accounting for medication duration, the number of patients in the GLP-1 agonist group who reached the primary end point was not statistically significant compared with the non-GLP-1 agonist group with a <em>P</em> value of 0.0772. There was not a statistically significant difference in the number of patients who achieved ≥ 10% and ≥ 15% weight loss between groups, whereas BMI change was statistically significantly greater in the GLP-1 agonist group.</div></div><div><h3>Conclusion</h3><div>A higher percentage of patients in the GLP-1 agonist group reached ≥ 5% weight loss as compared to patients in the non-GLP-1 agonist group, without regard to medication duration.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100046"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evaluation of treatment of chlamydia and gonorrhea in the emergency department at a military treatment facility","authors":"Carlo Tiano,&nbsp;Kayla Scheps,&nbsp;Amber Brammer","doi":"10.1016/j.japhpi.2025.100047","DOIUrl":"10.1016/j.japhpi.2025.100047","url":null,"abstract":"<div><h3>Background</h3><div>Sexually transmitted infections (STIs) have a major impact on global sexual and reproductive health. A systematic review of 13 studies involving emergency department (ED) patients who were tested and empirically treated for <em>Neisseria gonorrhoeae</em> (NG), <em>Chlamydia trachomatis</em> (CT), or both before receiving their nucleic acid amplification test results revealed that up to 84% of patients with positive test results were ultimately undertreated. Addressing this discrepancy is crucial for enhancing the quality of care for patients.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the impact of pharmacist-led interventions on the incidence of guideline-concordant empirical treatment for chlamydia and gonorrhea in patients presenting to the ED at a large academic military treatment facility (MTF).</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted at a large academic MTF ED from June 1, 2023, to September 30, 2023. Adult patients screened and treated for CT and NG were included. The primary outcome measured the percentage of patients who received empirical guideline-concordant treatment. Secondary outcomes included the number of patients untreated in the ED, patients who returned for treatment, and those lost to follow-up. After baseline data collection, a pharmacy-led in-service was conducted with educational handouts and education regarding the creation of an STI order set. A postintervention analysis was conducted from February 13, 2024, to April 30, 2024. Data were analyzed with descriptive statistics and chi-squared tests for categorical associations and means and SD for parametric data.</div></div><div><h3>Results</h3><div>In the preintervention group, 108 of 304 screened patients met inclusion criteria; 64 patients (59%) received concordant empirical treatment. After the intervention, 52 of 58 included patients (90%) received guideline-concordant treatment, showing a statistically significant improvement (<em>P</em> &lt; 0.001). Inappropriate treatment duration and dosage were common preintervention issues. After the intervention, adherence to guidelines improved, reducing inappropriate treatment cases.</div></div><div><h3>Conclusion</h3><div>A notable proportion of patients initially received inappropriate treatment. Implementing clinician education and order sets significantly improved compliance with treatment guidelines, demonstrating the effectiveness of targeted quality improvement initiatives.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 3","pages":"Article 100047"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144631654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of a hybrid heart failure clinic model on optimization of guideline-directed medical therapy","authors":"Matthew Aludino,&nbsp;Jasmine Stinson,&nbsp;Mark Bounthavong,&nbsp;Jennifer Namba,&nbsp;Trina Huynh,&nbsp;Andrew Willeford","doi":"10.1016/j.japhpi.2025.100056","DOIUrl":"10.1016/j.japhpi.2025.100056","url":null,"abstract":"<div><h3>Background</h3><div>Achieving rapid titration of guideline-directed medical therapy (GDMT) for patients with heart failure may be challenging due to limited clinical resources.</div></div><div><h3>Objective</h3><div>This study aimed to evaluate the effectiveness of a hybrid clinic model led by pharmacists in optimizing GDMT.</div></div><div><h3>Methods</h3><div>A single-center, retrospective analysis compared patients with an ejection fraction &lt; 50% seen in a hybrid clinic model that included multidisciplinary in-person visits and pharmacist-led telehealth appointments (hybrid) to an in-person model that included only a cardiology provider (historical). The primary end point was the number of GDMT medications prescribed per patient. An exploratory end point included a modified optimal medical therapy score (mOMT). Outcomes were analyzed using a linear mixed-effects model adjusting for baseline characteristics.</div></div><div><h3>Results</h3><div>Patients in the hybrid cohort (n = 52) increased from 2.5 to 3.1 GDMT at 3 months compared to 2.5 to 2.8 in the historical cohort (n = 46). There was a significantly greater increase in the average number of GDMT at each time interval in the hybrid cohort compared to the historical cohort (difference in changes per interval = +0.13; 95% CI: 0.05, 0.21). More patients were on quadruple therapy at the last study visit (48.1% vs 26.1%, <em>P</em> = 0.025), and the increase in mOMT was significantly higher in the hybrid cohort (difference in changes = +0.036; 95% CI: 0.015, 0.056).</div></div><div><h3>Conclusions</h3><div>The hybrid model involving pharmacists was associated with greater initiation of GDMT compared to in-person care without a pharmacist. This study confirms the valuable role of pharmacists in optimizing therapy for patients with heart failure.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 4","pages":"Article 100056"},"PeriodicalIF":0.0,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing evidence-based decision making through primary care provider–pharmacist collaboration and patient simulation training","authors":"Adam Chesler,&nbsp;Jessica Puckett-Beasley,&nbsp;Amir Shakouri,&nbsp;Michelle Borowski,&nbsp;David Eustis,&nbsp;David Paculdo,&nbsp;Isabella Cooney,&nbsp;John Paulo Vergara,&nbsp;Clive Fields,&nbsp;Trever Burgon","doi":"10.1016/j.japhpi.2025.100031","DOIUrl":"10.1016/j.japhpi.2025.100031","url":null,"abstract":"<div><h3>Background</h3><div>Traditionally, physicians’ and pharmacists’ roles have been distinct. However, an aging population, increasing prevalence of chronic conditions, the growth of value-based care payments, and forecasted shortfalls in primary care providers (PCPs) are forcing a rethinking of this paradigm. Creating opportunities for collaboration between PCPs and pharmacists presents an opportunity to address these challenges. This study explores the impact of this collaboration on evidence-based decision making at Village Medical and Walgreens.</div></div><div><h3>Methods</h3><div>Online simulated cases of patients with diabetes were randomly assigned to PCPs alone or PCP-pharmacist dyad pairs. The patient simulations were administered in 3 seasons in 2023, and participants completed the cases by making care decisions and receiving real-time feedback on improvement opportunities. Care decisions were scored against evidence-based guidelines. In the first season, PCPs completed cases alone to establish a practice baseline. For the next 2 seasons, 40 PCPs were each paired with a pharmacist and asked to complete their next 2 seasons of patient simulations together. Care decisions made by the dyad pairs were compared with 40 Village Medical matched PCPs completing the cases on their own.</div></div><div><h3>Results</h3><div>In the baseline season, we found no difference in the treatment domain between the predyad and control PCPs (64.0% vs. 63.2%, respectively). By the final season, treatment scores improved for both groups (up to 72.9% for the dyads and up to 68.9% for control), a difference-in-difference improvement of +3.2% for the dyads (<em>P</em> = 0.497). Stopping sulfonylureas and prescribing sodium-glucose cotransporter-2 inhibitors showed noteworthy difference-in-difference improvements among the dyads: +16.2% (<em>P</em> = 0.501) and +23.1% (<em>P</em> = 0.296), respectively.</div></div><div><h3>Conclusion</h3><div>This proof-of-concept study provides evidence that PCP-pharmacist collaboration can improve care decisions, especially in polypharmacy management, medication deprescribing, and evidence-based integration of new medications. The results support continued efforts to enhance collaboration between pharmacists and primary care to improve care quality.</div></div>","PeriodicalId":100737,"journal":{"name":"JAPhA Practice Innovations","volume":"2 2","pages":"Article 100031"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143833447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}